Glassman Wealth Services boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,866 shares of the company’s stock after purchasing an additional 126 shares during the quarter. Johnson & Johnson comprises approximately 0.5% of Glassman Wealth Services’ portfolio, making the stock its 18th biggest position. Glassman Wealth Services’ holdings in Johnson & Johnson were worth $1,916,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Morgan Stanley lifted its stake in Johnson & Johnson by 0.3% in the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock valued at $2,727,694,000 after buying an additional 54,563 shares during the last quarter. Price Wealth LLC lifted its stake in Johnson & Johnson by 8.6% in the second quarter. Price Wealth LLC now owns 1,270 shares of the company’s stock valued at $179,000 after buying an additional 101 shares during the last quarter. Financial Advisory Service Inc. lifted its stake in Johnson & Johnson by 2.5% in the second quarter. Financial Advisory Service Inc. now owns 17,970 shares of the company’s stock valued at $2,527,000 after buying an additional 431 shares during the last quarter. Abundance Wealth Counselors lifted its stake in Johnson & Johnson by 183.3% in the second quarter. Abundance Wealth Counselors now owns 7,109 shares of the company’s stock valued at $1,000,000 after buying an additional 4,600 shares during the last quarter. Finally, Adams Asset Advisors LLC lifted its stake in Johnson & Johnson by 178.6% in the second quarter. Adams Asset Advisors LLC now owns 15,980 shares of the company’s stock valued at $2,247,000 after buying an additional 10,245 shares during the last quarter. 67.44% of the stock is owned by hedge funds and other institutional investors.
NYSE:JNJ opened at $146.36 on Friday. The stock has a fifty day moving average price of $145.51 and a two-hundred day moving average price of $146.57. The stock has a market capitalization of $385.30 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. Johnson & Johnson’s revenue was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.12 earnings per share. On average, analysts predict that Johnson & Johnson will post 7.99 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.01 dividend. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date of this dividend is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
A number of equities research analysts have weighed in on JNJ shares. Cantor Fitzgerald boosted their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Credit Suisse Group upped their price target on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $164.93.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Story: Why Invest in Dividend Kings
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.